188 related articles for article (PubMed ID: 22405968)
21. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
[TBL] [Abstract][Full Text] [Related]
22. Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription.
Owen TA; Bortell R; Yocum SA; Smock SL; Zhang M; Abate C; Shalhoub V; Aronin N; Wright KL; van Wijnen AJ
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9990-4. PubMed ID: 2124710
[TBL] [Abstract][Full Text] [Related]
23. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
24. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.
Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB
Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163
[TBL] [Abstract][Full Text] [Related]
26. Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin.
Zajkowicz A; Gdowicz-Kłosok A; Krześniak M; Ścieglińska D; Rusin M
Cell Signal; 2015 Sep; 27(9):1677-87. PubMed ID: 25989210
[TBL] [Abstract][Full Text] [Related]
27. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
28. The RRM domain of MINT, a novel Msx2 binding protein, recognizes and regulates the rat osteocalcin promoter.
Newberry EP; Latifi T; Towler DA
Biochemistry; 1999 Aug; 38(33):10678-90. PubMed ID: 10451362
[TBL] [Abstract][Full Text] [Related]
29. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
30. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
32. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
33. Mdm2-dependent regulation of p53 expression during long-term potentiation.
Lisachev PD; Pustylnyak VO; Shtark MB
Bull Exp Biol Med; 2015 Jan; 158(3):333-5. PubMed ID: 25573363
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
36. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
38. The Notch-responsive transcription factor Hes-1 attenuates osteocalcin promoter activity in osteoblastic cells.
Zhang Y; Lian JB; Stein JL; van Wijnen AJ; Stein GS
J Cell Biochem; 2009 Oct; 108(3):651-9. PubMed ID: 19670267
[TBL] [Abstract][Full Text] [Related]
39. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
